Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Nadofaragene firadenovec-vncg in Non-Muscle Invasive Bladder Neoplasms: NCT06929286 Clinical Landscape Report 2026
15 October 2026
NCT06929286 clinical landscape for Non-Muscle Invasive Bladder Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Quisinostat Hydrochloride in Uveal Melanoma: NCT06932757 Clinical Landscape Report 2026
15 October 2026
NCT06932757 clinical landscape for Uveal Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Epcoritamab in Diffuse Large B-Cell Lymphoma: NCT06931652 Clinical Landscape Report 2026
15 October 2026
NCT06931652 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
HRXG-K-1939 in Rhabdomyosarcoma: NCT06932861 Clinical Landscape Report 2026
15 October 2026
NCT06932861 clinical landscape for Rhabdomyosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Aprepitant in Pruritus: NCT06931119 Clinical Landscape Report 2026
15 October 2026
NCT06931119 clinical landscape for Pruritus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Anti-BCMA/CD70 CAR-T cells(The Children's Hospital of Zhejiang University School of Medicine) in Systemic Lupus Erythematosus: NCT06934447 Clinical Landscape Report 2026
15 October 2026
NCT06934447 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
C-CAR168 in Lupus Nephritis: NCT06935474 Clinical Landscape Report 2026
15 October 2026
NCT06935474 clinical landscape for Lupus Nephritis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nivolumab in Metastatic Renal Cell Carcinoma: NCT06934057 Clinical Landscape Report 2026
15 October 2026
NCT06934057 clinical landscape for Metastatic Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Risvutatug Rezetecan in Osteosarcoma: NCT06935409 Clinical Landscape Report 2026
15 October 2026
NCT06935409 clinical landscape for Osteosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
JY-231 in B-Cell Lymphoma: NCT06940960 Clinical Landscape Report 2026
15 October 2026
NCT06940960 clinical landscape for B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
WTX-330 in Follicular Lymphoma: NCT06939283 Clinical Landscape Report 2026
15 October 2026
NCT06939283 clinical landscape for Follicular Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Iparomlimab/Tuvonralimab in Soft Tissue Neoplasms: NCT06939855 Clinical Landscape Report 2026
15 October 2026
NCT06939855 clinical landscape for Soft Tissue Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white space.